Oruka Therapeutics, Inc. (ORKA NASDAQ) stock market data APIs
$62.303
0.13(0.2%)
as of May 15, 2026
Try our APIs with
free plan!
Oruka Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Prev. Close
62.303
Open
62.4291
High
63.0645
Low
60.5876
52 wk Range
9.54-91
Market Cap
3 854 M
Shares Outstanding
60 312 K
EPS
-0.48
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Oruka Therapeutics, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oruka Therapeutics, Inc. data using free add-ons & libraries
Get Oruka Therapeutics, Inc. Fundamental Data
Oruka Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -133 289 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Oruka Therapeutics, Inc. Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: -0.5454
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oruka Therapeutics, Inc. News
New
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
Key Points Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end ...
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
Avidity Partners Management disclosed a buy of 259,700 shares of Enliven Therapeutics(NASDAQ:ELVN) in its May 13, 2026, SEC filing, an estimated $7.19 million transaction based on quarterly average pr...
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
On May 13, 2026, Avidity Partners Management disclosed a new position in Aktis Oncology(NASDAQ:AKTS), acquiring 468,566 shares in the first quarter. The estimated transaction value was $9.10 million b...
Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley
Halozyme Therapeutics (HALO) posted stronger-than-expected Q1 results, with revenue beating consensu PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Get Oruka Therapeutics, Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
